• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    OKYO Pharma Limited - Ordinary Shares (NQ: OKYO )

    1.640 UNCHANGED
    Streaming Delayed Price Updated: 3:57 PM EDT, Jul 23, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Price and Volume

    Detailed Quote
    Volume 0
    Open 1.640
    Bid (Size) 1.530 (1)
    Ask (Size) 1.660 (3)
    Prev. Close 1.640
    Today's Range 1.640 - 1.640
    52wk Range 1.090 - 3.070
    Shares Outstanding N/A
    Dividend Yield N/A
    Chart for (: )
    Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

    Top News

    More News
    Why ConAgra Brands Shares Are Trading Lower? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Via Benzinga
    OKYO Pharma to Initiate Neuropathic Corneal Pain Trial for OK-101
    From OKYO Pharma LTD
    Via GlobeNewswire

    Performance

    YTD
    -15.46%
    -15.46%
    1 Month
    +35.54%
    +35.54%
    3 Month
    +17.14%
    +17.14%
    6 Month
    +1.23%
    +1.23%
    1 Year
    +26.15%
    +26.15%

    More News

    Read More
    OKYO Pharma Announces Promising Categorical Data from OK-101 Phase 2 Trial in Dry Eye Disease
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Participation in May 2024 Investor Conferences
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at the Dry Horizons Symposium, a Partner Meeting of the Association for Research in Vision and Ophthalmology (ARVO)
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Reschedule Key Opinion Leader Event in Dry Eye Disease to May 2024
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Upcoming Presentation of OK-101 Phase 2 Data for Dry Eye Disease at Eyecelerator 2024, a Partner Meeting of the American Society for Cataract and Refractive Surgery
    From OKYO Pharma LTD
    Via GlobeNewswire
    Why Salarius Pharmaceuticals Shares Are Trading Higher By Around 31%; Here Are 20 Stocks Moving Premarket
    Via Benzinga
    Why Landos Biopharma Shares Are Trading Higher By Over 170%? Here Are Other Stocks Moving In Monday's Mid-Day Session
    Via Benzinga
    Relief For Dry Eye Disease? OKYO Pharma's Candidate Shows Durable Pain Relief In Mid-Stage Study
    Via Benzinga
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Multiple Signs and Symptoms of Dry Eye Disease including Ocular Pain Relief in its First-in-Human Phase 2 Trial of OK-101
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Host Key Opinion Leader Event to Discuss New and Comprehensive Data from Phase 2 Dry Eye Disease Trial
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Release New and Comprehensive Data from Phase 2 Dry Eye Disease Trial and Host Key Opinion Leader Event
    From OKYO Pharma LTD
    Via GlobeNewswire
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Intraday Session
    Via Benzinga
    12 Health Care Stocks Moving In Friday's Pre-Market Session
    Via Benzinga
    OKYO Pharma Receives FDA Approval of IND for OK-101 in Neuropathic Corneal Pain
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Distinguished Ophthalmologists with Expertise in the Medical and Surgical Treatment of Ocular Surface Diseases Join its Scientific Advisory Board
    From OKYO Pharma LTD
    Via GlobeNewswire
    12 Health Care Stocks Moving In Monday's After-Market Session
    Via Benzinga
    OKYO Pharma Announces OK-101 Successfully Achieved Statistical Significance for Both Sign and Symptom Endpoints in its First-in-Human Phase 2 Trial of OK-101 in Patients with Dry Eye Disease
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma to Present at the Biotech Showcase Conference in San Francisco, January 8-10, 2024
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces Last Patient Enrolled in OK-101 Phase 2 Clinical Trial to Treat Dry Eye Disease Has Completed Final Protocol Visit
    From OKYO Pharma LTD
    Via GlobeNewswire
    OKYO Pharma Announces $5.84 Million Cash Raise and Payables Reduction
    From OKYO Pharma LTD
    Via GlobeNewswire
    Dow Rebounds, Still Below Fair Value
    Via Talk Markets
    Topics Stocks
    Exposures US Equities
    Data & News supplied by www.cloudquote.io
    Stock quotes supplied by Barchart
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.